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Office of In Vitro Diagnostics and Radiological 
Health, FDA 
 
November 21, 2014 
DISCLAIMER 
• Thoughts presented here regarding new policy / 
regulatory issues are preliminary and do not represent 
finalized FDA policy 
 
• FDA cannot comment on specific investigations. 
Evolution of Translational Omics: 
Lessons Learned and the Path Forward 
(Institute of Medicine, 2012) 
“The committee recommends that FDA communicate the IDE 
requirements for use of omics-based tests in clinical trials to the Office 
of Human Research Protections (OHRP), IRBs, and other relevant 
institutional leadership…IRBs often lack knowledge of the IDE 
requirements compared to their understanding of the IND requirements; 
thus, clarification and education by FDA about IDE requirements are 
necessary. This communication could be conducted online and via 






Center for Drug Evaluation and 
Research 
Center for Biologics Evaluation and 
Research 
Center for Devices and Radiological 
Health 








Division of Immunology and Hematological Devices 
Division of Molecular Genetics and Pathology 
Division of Microbiology Devices 
Division of Chemistry and Toxicology Devices 
Division of Radiological Health 
Division of Mammography Quality Standards 
IVD Regulation 
• In Vitro Diagnostic tests (IVDs) are a critical component 
of current clinical care, influencing 80% of all clinical 
decision-making. 
 
• Through the 1976 medical device amendments to the 
FFDCA, FDA has the authority to regulate all laboratory 
tests, regardless of whether they are commercially 
distributed or developed by a laboratory. 
 
• FDA is charged with ensuring that IVDs are safe and 
effective (do what they say they will do) for their intended 
use so that patients are not unnecessarily harmed. 
 
Benefits of FDA Oversight 
• Independent Premarket Review 
– Independent assessment occurs prior to clinical use of test 
– Ensures test limitations are described 
– Ensures test performance claims are supported 
 
• Clinical Validation 
– Provide assurances that test provides clinically meaningful results  
 
• Post Market Surveillance and Post Market Controls 
– Mechanism to assist manufacturers and FDA in identifying problems 
with tests and assuring the performance of the IVD through out its 
life cycle 
 
• Oversight of Investigational-Stage Devices 
– Ensures acceptable risk-benefit ratio in clinical investigations of 
devices to protect study subjects 
In Vitro Diagnostics (IVDs)  
• In vitro diagnostic devices include “…those reagents, instruments, and 
systems intended for use in the diagnosis of disease or other conditions, 
including a determination of the state of health, in order to cure, mitigate, 
treat, or prevent disease or its sequelae. Such products are intended for 
use in the collection, preparation, and examination of specimens taken 
from the human body. These products are devices as defined in section 




• Intended use:  How will the device will be used in the therapeutic product 
trial? Encompasses: 
– Analyte to be detected 
– Type of result (quantitative, semi-quantitative, qualitative) 
– Specimen type(s) 
– Disease to be screened, monitored, treated, or diagnosed 












MammaPrint® is a qualitative in vitro diagnostic test service, performed in a single 
laboratory, using the gene expression profile of fresh frozen breast cancer 
tissue samples to assess a patients' risk for distant metastasis. 
The test is performed for breast cancer patients who are less than 61 years old, 
with Stage I or Stage II disease, with tumor size <= 5.0 cm and who are lymph 
node negative.  The MammaPrint® result is indicated for use by physicians as a 








 What assay measures, how to use results 
Intended Use  
Types of studies depend on IU claims;  
Less dependent on the technology or assay format 
Things that are or can be medical 
devices include: 
• Instrumentation 
• In vitro diagnostic kits 
• Reagents used for laboratory 
testing 
• Some apps 
• Software 
• Algorithms 
Medical devices are subject to regulatory requirements even 
though they may only be investigational.  
IVDs: Companion Diagnostics 
• Companion diagnostics are IVDs 
 
• An IVD companion diagnostic device is an in vitro diagnostic device 
that provides information that is essential for the safe and effective 
use of a corresponding therapeutic product. 
– Note: it is important to recognize, for example, that when a validated prognostic 
test is used to select patients for treatment, the ability to select patients who are 
expected to benefit from the treatment is an investigational use for which the test 
has not been validated until the investigational therapeutic product has 
demonstrated safety and efficacy in the test-selected population. 
• Drugs and their companion tests refer to each other in their labels. 













Protect human subjects 
PMA or 510k 
Assure safety and 
effectiveness 
Risk-Based Classification 
• For IVDs, the risk is based on the consequences of a false 
result 
• Examples: 
– High risk – HIV 
– Lower risk – pregnancy 
• 3 classification levels 
– Class I: common, low-risk devices – 510k (usually exempt) 
– Class II: more complex, moderate risk – 510k 
– Class III: most complex, high risk - PMA 
Elements of FDA Premarket Review 
• Analytical validity 
– Correctly detects analyte 
– Accuracy, precision, limits of detection/measurement 
• Clinical validity 
– Correctly identifies disease/condition 
– Clinical sensitivity, clinical specificity, predictive values 
• Labeling 
 
•  The MiSeqDx Platform is a sequencing instrument that measures fluorescence 
signals of labeled nucleotides through the use of instrument specific reagents 
and flow cells (MiSeqDx Universal Kit 1.0), imaging hardware, and data analysis 
software. The MiSeqDx Platform is intended for targeted sequencing of human 
genomic DNA from peripheral whole blood samples. The MiSeqDx Platform is 
not intended for whole genome or de novo sequencing. 
 
•  The MiSeqDx Universal Kit 1.0 is a set of reagents and consumables used in 
the processing of human genomic DNA samples derived from peripheral whole 
blood, and in the subsequent targeted re-sequencing of the resulting sample 
libraries. User-supplied analyte specific reagents are required for the preparation 
of libraries targeting specific genomic regions of interest. The MiSeqDx 
Universal Kit 1.0 is intended for use with the MiSeqDx instrument. 
Illumina MiSeqDxTM Platform and Universal Kit 1.0 
Illumina MiSeqDxTM Cystic Fibrosis 139 Variant 
Assay 
The Illumina MiSeqDx™ Cystic Fibrosis 139-Variant Assay is a qualitative in vitro diagnostic 
system used to simultaneously detect 139 clinically relevant cystic fibrosis disease-causing 
mutations and variants of the cystic fibrosis transmembrane conductance regulator (CFTR) 
gene in genomic DNA isolated from human peripheral whole blood -specimens. The variants 
include those recommended in 2004 by the American College of Medical Genetics (ACMG) 
and in 2011 by the American College of Obstetricians and Gynecologists (ACOG). The test is 
intended for carrier screening in adults of reproductive age, in confirmatory diagnostic testing 
of newborns and children, and as an initial test to aid in the diagnosis of individuals with 
suspected cystic fibrosis. The results of this test are intended to be interpreted by a board-
certified clinical molecular geneticist or equivalent and should be used in conjunction with 
other available laboratory and clinical information.  
 
This test is not indicated for use for newborn screening, fetal diagnostic testing, pre-
implantation testing, or for standalone diagnostic purposes.  
 
-The test is intended to be used on the Illumina MiSeqDx™ instrument.  
The Illumina MiSeqDxTM Cystic Fibrosis Clinical Sequencing Assay is a targeted 
sequencing in vitro diagnostic system that re-sequences the protein coding regions 
and intron/exon boundaries of the Cystic Fibrosis Transmembrane Conductance 
Regulator (CFTR) gene in genomic DNA isolated from human peripheral whole 
blood specimens collected in K2EDTA. The test detects single nucleotide variants, 
and small InDels within the region sequenced, and additionally reports on two deep 
intronic mutations and two large deletions. The test is intended to be used on the 
Illumina MiSeqDx Instrument. The test is intended to be used as an aid in the 
diagnosis of individuals with suspected cystic fibrosis (CF). The test is most 
appropriate when the patient has an atypical or non-classic presentation of CF or 
when other mutation panels have failed to identify both causative mutations. The 
results of the test are intended to be interpreted by a board-certified clinical 
molecular geneticist or equivalent and should be used in conjunction with other 
available information including clinical symptoms, other diagnostic tests, and family 
history. This test is not indicated for use for stand-alone diagnostic purposes, fetal 
diagnostic testing, for pre-implantation testing, carrier screening, newborn 
screening, or population screening.  
Illumina MiSeqDxTM Cystic Fibrosis Clinical 
Sequencing Assay 
Lessons from the Illumina Clearances 
Separation of tool and clinical claims 
Tool: MiSeqDx instrument 
Use: Sequences DNA 
 
Analytical validation 
• Clinical and cell line samples 
• Well-standardized panel with known 
variants 
• Performance demonstrated on a 
representative set of variants 
 
Clinical validation not needed 
Clinical: CF 139 variant and whole gene 
tests 
Use: Sequences 139 variants or whole 
CFTR gene  
 
Analytical validation 
• Specific validation of 139 variants, plus 
validation of CFTR normal sequence 
Clinical validation 
• Use of the CFTR2 database (JHU) for 
evidence 
What is an investigation? 
• Investigation means a clinical investigation or research 
involving one or more subjects to determine the safety or 
effectiveness of a device. 
Definition of “Subject” for Investigations 
• Subject means a human who participates in an 
investigation, either as an individual on whom or 
on whose specimen an investigational device is 
used or as a control. A subject may be in normal 
health or may have a medical condition or 
disease. 
 
What is an Investigational Device? 
• Investigational device means a device…that is the object of 
an investigation. 
 
• An investigational IVD is not legally marketed for the intended 
use or indication for use identified in that study, whether or not 
it has been previously cleared or approved for a separate 
intended use. 
 
• Important to distinguish from off-label use or practice of 
medicine. 
 
• Investigational use requires an exemption from premarket 
approval requirements for new drugs and devices. 
 






excluded from trial 
and/or receive SOC 
Test result influences treatment. 
placebo or 
comparator 
MARKER USED FOR STRATIFICATION 
investigational IVD 









Test result does not influence treatment. 
Other trial designs 
• Adaptive 
 
• Basket trials 
IDE Regulation (21 CFR 812) 
• “…purpose…is to encourage, to the extent consistent with the 
protection of public health and safety and with ethical 
standards, the discovery and development of useful devices 
intended for human use, and to that end to maintain optimum 
freedom for scientific investigators in their pursuit of this purpose.” 
• An IDE is a regulatory submission that permits clinical 
investigation of devices/IVDs. 
• An approved IDE permits a device to be shipped lawfully for the 
purpose of conducting investigations of the device without 
complying with other requirements of the Food, Drug, and 
Cosmetic Act (Act) that would apply to devices in commercial 
distribution.  
• Focused on risk 
• Delegated responsibilities 
 Several parts of the Code of Federal Regulations (21 CFR) 
pertain to IDEs:  
   
• Part 812 - Investigational Device Exemptions  
• Part 50 - Protection of Human Subjects and Informed 
Consent 
• Part 54 - Financial Disclosure of Investigators  
• Part 56 - Institutional Review Boards 
• Part 820 Section 30 – Design Controls (Quality Systems 
Regulation) 




– Registration and listing 
– Performance standards 
– Premarket notification 
– Premarket approval 
– Banned device regulation 
– Restricted device regulation 
– Good manufacturing practice/Quality System 
regulations (except design controls) 
IDE approval aims to ensure that: 
• Risks are outweighed by anticipated benefits to 
subjects and importance of knowledge to be 
gained. 
• Informed consent is adequate. 
• Investigation is scientifically sound. 
IDE submission Risk determination Investigational IVD 
Safety Risk only Intended Use 
      All Device Investigations 
Studies Exempt from 
the IDE Regulation 
Studies Subject to the IDE 
Regulation 
Non-Significant Risk (NSR) 
Abbreviated 
Requirements 
Significant Risk (SR) 
Full Requirements 
IDE Requirements (non-inclusive) 
• Detailed in 21CFR812.20  
• Fully specified device  
• Sufficient analytical validation and clinical information 
– Does the test measure the correct analyte reliably? 
• Pre-specified investigational plan 
• Informed consent – Include, as part of the IDE, the actual text 
of the Informed consent that will be used in the proposed 
study. 
• If there are physician investigators in the study ensure that 
they have a current license to practice medicine, and this will 
be included in the IDE and subsequent annual reports. 
IDE: A Risk-Based Approach to IVD 
Regulation 
• IDE requirements depend on the risk of the test use to 
study subjects in the investigation. 
• For IVD tests, it is important to think about the risks 
associated with erroneous test results.  What would 
happen if the test results are wrong? 
– False positive or false negative results mean that a patient may 
be diverted from therapeutic options which may be more 
beneficial to them. 
– Patients may be subject to adverse events from the 
investigational trial when they are not intended to be the subject 
of the investigation. 31 
IDE Exempt 
• 812.2(c)(3): A diagnostic device [is exempt], if the sponsor complies 
with applicable requirements in 809.10(c) [labeling] and if the 
testing: 
– (i) Is noninvasive, 
– (ii) Does not require an invasive sampling procedure that presents 
significant risk, 
– (iii) Does not by design or intention introduce energy into a subject, and 
– (iv) Is not used as a diagnostic procedure without confirmation of the 
diagnosis by another, medically established diagnostic product or 
procedure. 
• Example: Use of an in vitro diagnostic in a retrospective study of 
accrued specimens (without return of results). 
• Depends on interpretation of “medically established”. 
Nonsignificant risk (NSR) 
• Does not meet the definition of significant risk (SR) in 812.3(m). 
• Abbreviated requirements: 
– Labeling (812.5) 
– IRB approval 
– Informed consent (part 50) 
– Monitoring (812.46) 
– Records (812.140) and reporting (812.150) (sponsor and 
investigator) 
– Prohibition against promotion and other practices (812.7.) 
• No IDE application to the FDA required. Meeting the abbreviated 
requirements (including IRB approval!) means that you have an 
approved application for an IDE. 
• Example: Use of an investigational IVD test to stratify patients for 
treatment in a clinical trial. 
Significant Risk (SR) 
• Significant risk device (812.3(m)) means an investigational device 
that: 
– 1) Is intended as an implant and presents a potential for serious 
risk to the health, safety, or welfare of a subject; 
– (2) Is purported or represented to be for a use in supporting or 
sustaining human life and presents a potential for serious risk to 
the health, safety, or welfare of a subject; 
– (3) Is for a use of substantial importance in diagnosing, curing, 
mitigating, or treating disease, or otherwise preventing 
impairment of human health and presents a potential for serious 
risk to the health, safety, or welfare of a subject; or 
– (4) Otherwise presents a potential for serious risk to the health, 
safety, or welfare of a subject. 
• Example: Use of an in vitro diagnostic test to select patients for a 
clinical trial. 
• Accrual by test result 
• Rx assignment 
• Safety signal for Rx 
• Targeted biomarker 
• Invasive sampling 
• All-comers accrual 
• Stratification 
• No “known effective” Rx 
• Convenience biomarker 
• Non-invasive sampling 
BALANCED APPROACH TO IVD RISK 
Context and effect of an incorrect test result 
More Risk Less Risk Cancer is a 
serious disease.  
Any effect on a 
treatment decision 
arising from IVD 
use poses 
significant risk. 
Cancer is a 
serious disease.  
Large and unmet 
medical need 
makes any IVD 
risk minor. 
Some Features with Lesser Relevance for 
IVD Risk Determination 
• Size of trial 
• Access to “other trials” 
• Clinical trial phase 
 
Assessing Risk 
1. Will use of the investigational test results lead to some trial subjects 
foregoing or delaying a treatment that is known to be effective? 
2. Will use of the investigational test results expose trial subjects to 
safety risks (e.g., adverse events from the experimental therapy) 
that (in some “net” sense) exceed the risks encountered with 
control therapies or non-trial standard of care? 
3. Is it likely, based on a priori information about the investigational 
therapy, that incorrect test results would degrade the safety or 
efficacy of subjects’ treatment? 
4. Does specimen acquisition, done for investigational testing and 
outside the standard of care, require an invasive sampling 
procedure that presents significant risk? 
Risk in Investigations Using Genetic Testing 
• What are the clinical indications for testing? 
• Are the results confirmed by an acceptable technique? What is an 
acceptable technique? 
• Are results returned? 
• Will results be placed in the medical record? 
• How are results communicated to the treating physician? 
• What are the risks of an incorrect test result? 
– What clinical actions might be taken based on test results? 
– How urgent are the results? 
• For genetic testing, risk may depend on the disease; the risks of 
treatment/procedure(s) after a screen positive result; the 




Risk in Ongoing Trials 
• Risk can change during the course of a trial. 
– Adaptive trials 
– Protocol changes 
– New information (DSMB review) 
 
• If IVD use becomes SR in the middle of a trial, an IDE is 
required. 
 
• Ongoing surveillance is recommended. 
Delegated Responsibilities and Risk Determination 
• Sponsor makes initial determination and 








• FDA can help; FDA determination is final 
FDA Policy for CDx Trials 
 
• SR IVD: An IDE is required for an investigation even if there is an 
IND for use of the drug, or if the drug is IND exempt. 
 
• NSR IVD: An IDE is not required, and cannot be accepted for 
review. 
– The trial still has to comply with the abbreviated requirements. 
– Some information on the test may be requested in the IND. 
– A presub with CDRH is recommended. 
 
• A trial may not proceed until it has received IND and/or IDE approval 
AND IRB approval. 
Common Problems 
• Failure to recognize that the biomarker test is an 
investigational medical device. 
• Expectation that compliance with IND regulation is sufficient 
to satisfy requirements under the IDE regulation. 
• Risk misdetermination. If the IRB agrees the device is NSR, 
FDA will never see a submission, and will be unaware of the 
trial. 
• Change in risk during course of trial. 
43 
IDE Submissions 
• Sponsor submits IDE application to FDA for SR studies 
• FDA approves, approves with conditions, or disapproves 
IDE within 30 calendar days 
• Sponsor obtains IRB approval  
• After both FDA and IRB approve the investigation, study may 
begin 
• Changes  amendments 
• New studies with the same device  supplements 
• “Approved with Conditions” signifies that the study may 
begin, but that certain conditions have been stipulated and 
must be met by the sponsor within 45 calendar days 




• Example of “approved with conditions” letter: 
 Your application is conditionally approved, and you may begin your 
investigation at the following institutions after you have obtained IRB 
approvals and submitted certifications of IRB approvals to FDA: 
Centers X, Y, and Z. Your investigation is limited to 3 institutions and 
20 subjects. 
 
 This approval is being granted on the condition that, within 45 days 







IDE Requirements (non-inclusive) 
• Fully specified device  
• Sufficient analytical validation and clinical information  
• Pre-specified investigational plan 
• Informed consent – Include, as part of the IDE, the 
actual text of the Informed consent that will be used in 
the proposed study. 
• If there are physician investigators in the study ensure 
that they have a current license to practice medicine, 
and this will be included in the IDE and subsequent 
annual reports. 
What’s in an IDE Application? 
• Detailed in 21 CFR 812.20 
• Administrative elements 
• Report of prior investigations 










•Additional records and reports 
Analytical Performance/Validity in an IDE  
• Does the test measure the correct analyte? 
 
• Does the test measure the analyte reliably? 
 
• Precision, reproducibility, sensitivity, specificity, etc. 
 
• Risk dependent. The extent of analytical validation required 
for a pivotal trial exceeds what is required for feasibility 
studies. 
 
• For a companion diagnostic, analytical performance around 
the cutoff/reference range is critical. 
Some common misconceptions: 
• It is not a test, it is a process. 
• It is not an IVD if it is in the research and development 
stage. 
• It is not an IVD if I don’t plan to market the test. 
• The IDE regulation does not apply if I don’t plan to 
market the test. 
• I have CLIA certification, so I don’t need to worry about 
the IDE regulation. 
• I can never generate enough data to submit an IDE. 
Interacting with FDA…for Sponsors 
PRESUBMISSION 
• You can meet with the FDA for nonbinding discussions and advice: 
o before conducting studies, including clinical trials 
o before submitting a marketing application 
• This is an opportunity to address new scientific and regulatory issues. 
• Particularly important when developing new technologies. 




DURING REVIEW OF A SUBMISSION 
• Acceptance Review Communication 
• Substantive Interaction 
• Interactive Review 
Resources 




– IRB Responsibilities for Reviewing the Qualifications of Investigators, Adequacy of 
Research Sites, and the Determination of Whether an IND/IDE is Needed. 
http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM328855.pdf 
– FDA Decisions for Investigational Device Exemption (IDE) Clinical Investigations. 
http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceD
ocuments/UCM279107.pdf 
– Significant Risk and Nonsignificant Risk Medical Device Studies. 
http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM126418.pdf 
– Others at www.fda.gov 
 
• Device Advice 
– http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/default.htm 
 
• CDRH Learn (including information about sponsor responsibilities, 
investigator responsibilities, IRBs, and the Bioresearch Monitoring 
Program) 
– http://www.fda.gov/Training/CDRHLearn/default.htm  
Other FDA efforts 
• Educational  
– Conferences 
– Discussion with IRBs, academic investigators, and institutions 
• Work with NIH to disseminate information early in the 
granting process 
• FDA outreach 
– Presentations and presence at meetings 
– Webinars 
– Guidance, etc. 
• FDA participation in internal and external working groups 
• Workshops 
• Other opportunities 
 
Thank you! 
E. David Litwack, PhD 
ernest.litwack@fda.hhs.gov 
 
